ReviewProgress in retinal and eye research2021
Discovery and clinical translation of novel glaucoma biomarkers.
Review in Progress in retinal and eye research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.American journal of ophthalmology · 2022Trial
- Reflective broadband adaptive optics scanning light ophthalmoscope with 20 D focus range.Biomedical optics express · 2026Article
- Nocturnal Intraocular Pressure Monitoring With a Soft Contact Lens Sensor for Glaucoma Management.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- IL-1-mediated vitreous inflammation as an early indicator of retinal ganglion cell loss following acute optic nerve injury.Journal of neuroinflammation · 2026Article
- Automated montaging and contrast stretching of adaptive optics ophthalmoscope images.Biomedical optics express · 2026Article
- Cargo molecules in plasma neural-derived extracellular vesicles reveal pathological signatures of primary open-angle glaucoma.Journal of translational medicine · 2026Article
- Retinal Ganglion Cell Degeneration in Glaucoma: Systematic Review.Bioengineering (Basel, Switzerland) · 2026Review
- Prediction of primary glaucoma: development and validation of multiple machine learning models.Scientific reports · 2026Article
- Plasma Proteomic Dynamics Preceding Glaucoma Reveal a 15-Year Pre-Diagnostic Window: Causal Insights and Predictive Utility in 45,850 Participants.Investigative ophthalmology & visual science · 2026Article
- Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Synaptic control of retinal ganglion cell survival and axon regeneration.Molecular neurodegeneration · 2026Review
- Risk of Glaucoma after Pars Plana Vitrectomy in a Large Federated Health Record Network.Ophthalmology science · 2026Article
- Serum Alpha-1-Antitrypsin and Folic Acid as Biomarkers for Glaucoma Risk.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Vitreous Inflammation as an Early Indicator of Retinal Ganglion Cell Loss Following Acute Optic Nerve Injury in Mice.bioRxiv : the preprint server for biology · 2025Article
- Wide-field cellular-resolution retinal imaging using deformable mirror-based sensorless adaptive optics time-domain full-field OCT.Biomedical optics express · 2025Article
- Zilebesiran as an Innovative siRNA-Based Therapeutic Approach for Hypertension: Emerging Perspectives in Cardiovascular Medicine.International journal of molecular sciences · 2025Review
- Ophthalmic drug discovery and development using artificial intelligence and digital health technologies.NPJ digital medicine · 2025Review
- Enhanced genotype-phenotype analysis using multimodal adaptive optics and 3D protein structure in Bietti Crystalline Dystrophy.American journal of ophthalmology case reports · 2025Article
- Non-human primates as preclinical models for optic nerve research: advancing insights into their application and potential.Eye (London, England) · 2025Review
- Tear-derived extracellular vesicles as diagnostic biomarkers for ocular and neurodegenerative diseases: opportunities and challenges.Extracellular vesicles and circulating nucleic acids · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glaucoma and other optic neuropathies are characterized by progressive dysfunction and loss of retinal ganglion cells and their axons. Given the high prevalence of glaucoma-related blindness and the availability of treatment options, improving the diagnosis and precise monitoring of progression in these conditions is paramount. Here we review recent progress in the development of novel biomarkers for glaucoma in the context of disease pathophysiology and we propose future steps for the field, including integration of exploratory biomarker outcomes into prospective therapeutic trials. We anticipate that, when validated, some of the novel glaucoma biomarkers discussed here will prove useful for clinical diagnosis and prediction of progression, as well as monitoring of clinical responses to standard and investigational therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.